Dyadic International, Inc. (DYAI): Modelo de negócios Canvas [Jan-2025 Atualizado]

A Dyadic International, Inc. (Dyai) fica na vanguarda da biotecnologia revolucionária, empunhando sua inovadora plataforma de expressão de células C1 para transformar a produção de enzimas industriais e a engenharia genética. Esta empresa inovadora preenche a lacuna entre pesquisas científicas de ponta e aplicações industriais práticas, oferecendo soluções transformadoras que abrangem setores farmacêuticos, agrícolas e renováveis. Ao alavancar estrategicamente suas tecnologias proprietárias e abordagem colaborativa, a Dyai não está apenas desenvolvendo enzimas, mas reimaginando como os sistemas biológicos podem ser otimizados para a eficiência e a sustentabilidade sem precedentes.

Dyadic International, Inc. (Dyai) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa e universidades de pesquisa de biotecnologia

Diádico International colabora com as seguintes instituições de pesquisa:

Instituição	Foco de colaboração	Ano estabelecido
Universidade da Flórida	Pesquisa em tecnologia enzimática	2018
Universidade Estadual da Carolina do Norte	Sistemas de expressão de proteínas	2019

Empresas farmacêuticas e agrícolas

As principais parcerias farmacêuticas e agrícolas incluem:

• Bayer Cropscience
• Novozimas
• Biosciências industriais de Dupont

Colaboradores de desenvolvimento de tecnologia enzimática

As parcerias de desenvolvimento enzimático envolvem:

Colaborador	Foco em tecnologia	Valor do contrato
Codexis, Inc.	Engenharia de proteínas	US $ 1,2 milhão (2023)
Genomatica	Otimização da enzima industrial	$850,000 (2023)

Agências de financiamento de pesquisa governamental

Fontes de financiamento do governo:

• National Science Foundation (NSF) - Grant de US $ 750.000 (2023)
• Departamento de Energia - Financiamento de Pesquisa de US $ 1,1 milhão
• Institutos Nacionais de Saúde - Suporte de Pesquisa de US $ 500.000

Dyadic International, Inc. (DYAI) - Modelo de negócios: Atividades -chave

Desenvolvimento e otimização de enzimas

O Diádico Internacional se concentra no desenvolvimento e otimização de enzimas para aplicações industriais de biotecnologia. Em 2023, a empresa investiu US $ 2,3 milhões em pesquisa e desenvolvimento enzimáticos.

Área de pesquisa	Investimento ($)	Estágio de desenvolvimento
Otimização de enzimas	2,300,000	Avançado
Engenharia de proteínas	1,750,000	Em andamento

Pesquisa de Engenharia Genética

A empresa realiza extensa pesquisa de engenharia genética usando sua plataforma proprietária de expressão de células C1.

• Pessoal de pesquisa: 12 engenheiros genéticos em tempo integral
• Orçamento de pesquisa anual: US $ 4,1 milhões
• Aplicações de patentes: 7 em 2023

Inovação do processo biomanufature

A Diadic International é especializada no desenvolvimento de processos inovadores de biomanufatura para aplicações industriais.

Tipo de processo	Projetos atuais	Valor potencial de mercado
Produção de enzimas	3 projetos ativos	US $ 12,5 milhões
Expressão de proteínas	2 desenvolvimentos em andamento	US $ 8,3 milhões

Plataforma de expressão de células C1 proprietária de licenciamento

A empresa gera receita através do licenciamento de seu Plataforma de expressão de células C1.

• Licenciados atuais: 5 empresas de biotecnologia
• Receita de licenciamento em 2023: US $ 3,6 milhões
• Faixas de licenciamento: US $ 500.000 - US $ 1,2 milhão por contrato

Desenvolvimento de soluções industriais de biotecnologia

A Diádica Internacional cria soluções de biotecnologia para vários setores industriais.

Setor da indústria	Soluções desenvolvidas	Aplicações em potencial
Farmacêutico	3 plataformas enzimáticas	Terapêutica proteica
Agrícola	2 sistemas enzimáticos	Melhoramento da colheita
Produtos químicos industriais	1 plataforma avançada	Produção sustentável

Dyadic International, Inc. (DYAI) - Modelo de negócios: Recursos -chave

Tecnologia proprietária de plataforma de expressão de células C1

Diádico Plataforma de expressão de células C1 Representa um recurso -chave crítico para as operações de biotecnologia da empresa.

Métrica de tecnologia	Valor específico
Anos de desenvolvimento da plataforma	Mais de 15 anos de pesquisa e otimização
Eficiência de expressão	Até 10x de produção de proteínas mais rápidas em comparação com as plataformas tradicionais
Potencial de redução de custos	Estimada de 50 a 70% de redução nos custos de produção

Portfólio de propriedade intelectual

O diádico mantém uma estratégia de propriedade intelectual robusta.

Categoria IP	Número de ativos
Patentes ativas	23 patentes concedidas
Aplicações de patentes	12 Aplicações pendentes
Cobertura geográfica	Estados Unidos, Europa, Ásia

Equipe de Pesquisa e Desenvolvimento Científica

Os recursos de P&D da Dyadic são ancorados por seu pessoal científico especializado.

• Pessoal total de P&D: 38 pesquisadores em tempo integral
• Ph.D. Cientistas de nível: 22 membros da equipe
• Experiência média de pesquisa: 12,5 anos

Instalações de Laboratório de Biotecnologia Avançada

A empresa opera sofisticada infraestrutura de pesquisa.

Especificação da instalação	Detalhes
Espaço total de laboratório	7.500 pés quadrados
Nível de biossegurança	Instalações certificadas BSL-2
Investimento de equipamentos	US $ 4,2 milhões em infraestrutura de laboratório atual

Experiência especializada em engenharia genética

Os recursos de engenharia genética da Dyadic representam uma competência central.

• Técnicas de modificação genética especializadas: CRISPR, DNA recombinante
• Experiência interdisciplinar: biologia molecular, engenharia de proteínas
• Redes de pesquisa colaborativa: 6 parcerias acadêmicas e da indústria

Dyadic International, Inc. (DYAI) - Modelo de negócios: proposições de valor

Tecnologia avançada de produção de enzimas

A plataforma de expressão C1 da Dyadic International gera enzimas com as seguintes especificações:

Métrica	Desempenho
Rendimento da expressão de proteínas	Até 20 gramas por litro
Eficiência de produção	40% maior que os sistemas tradicionais
Faixa de estabilidade enzimática	-20 ° C a 50 ° C.

Soluções de biomanufatura econômicas

Métricas de redução de custos para biomanufatura:

• Redução de custos de produção: 35% em comparação com as plataformas convencionais
• Redução do tempo de fabricação: 50% de processamento mais rápido
• As despesas operacionais diminuíram: US $ 0,50 por grama de proteína

Plataformas sustentáveis ​​de biotecnologia

Métricas de sustentabilidade ambiental:

Parâmetro de sustentabilidade	Desempenho
Redução da pegada de carbono	62% mais baixo em comparação aos métodos tradicionais
Eficiência de uso de água	75% menos consumo de água
Consumo de energia	45% de requisitos de energia mais baixos

Sistemas de expressão de proteínas de alto desempenho

Capacidades de expressão de proteínas:

• Faixa de expressão: 1-20 gramas por litro
• Precisão de glicosilação: 98,5% de precisão
• Eficiência de dobragem de proteínas: taxa de sucesso de 92%

Aplicações versáteis em vários setores

Indústria	Aplicativo	Potencial de mercado
Farmacêutico	Produção de proteínas recombinantes	Segmento de mercado de US $ 45 bilhões
Agrícola	Desenvolvimento enzimático	US $ 6,2 bilhões de mercado potencial
Biotecnologia Industrial	Biocatálise	Oportunidade de mercado de US $ 12,7 bilhões

Dyadic International, Inc. (DYAI) - Modelo de negócios: Relacionamentos ao cliente

Suporte técnico e consulta

A Diádica Internacional fornece suporte técnico especializado para tecnologias de produção de enzimas e proteínas. A partir de 2024, a empresa oferece:

• Serviços diretos de consulta científica
• Equipe de suporte técnico dedicado com experiência em engenharia enzimática
• Orientação personalizada para aplicações de biotecnologia industrial

Categoria de suporte	Tempo de resposta	Interações de suporte anual
Suporte técnico básico	48 horas	250-300 interações com os clientes
Consulta premium	24 horas	75-100 consultas especializadas

Parcerias de pesquisa colaborativa

O diádico mantém colaborações estratégicas de pesquisa com várias instituições industriais e acadêmicas.

• Parcerias de pesquisa ativa: 12-15 colaborações simultâneas
• Investimento anual em pesquisa colaborativa: US $ 1,2-1,5 milhão
• Áreas de foco: biofarmacêutica, enzimas industriais, biotecnologia agrícola

Plataformas de tecnologia de licenciamento

A empresa licencia sua plataforma de expressão C1 proprietária para empresas de biotecnologia e farmacêutica.

Categoria de licenciamento	Número de licenciados	Receita média de licenciamento
Licenciamento exclusivo	3-4 empresas	US $ 500.000 - US $ 750.000 por licença
Licenciamento não exclusivo	7-9 empresas	US $ 150.000 - US $ 300.000 por licença

Serviços de desenvolvimento de enzimas personalizadas

A diádica oferece soluções de engenharia enzimática personalizadas para aplicações industriais específicas.

• Projetos de desenvolvimento de enzimas personalizadas: 20-25 anualmente
• Duração média do projeto: 6-9 meses
• Faixa de valor do projeto: US $ 250.000 - US $ 1,5 milhão

Compartilhamento de conhecimento científico

A empresa participa ativamente da disseminação do conhecimento científico por meio de vários canais.

Plataforma de compartilhamento de conhecimento	Engajamento anual	Alcançar
Conferências científicas	6-8 apresentações	Comunidade internacional de biotecnologia
Publicações revisadas por pares	4-6 trabalhos de pesquisa	Revistas científicas globais
Webinars e workshops	10-12 eventos	300-500 participantes por evento

Dyadic International, Inc. (Dyai) - Modelo de Negócios: Canais

Equipe de vendas diretas

A partir de 2024, a Diádica Internacional mantém uma equipe de vendas direta especializada focada nos mercados de biotecnologia e produção de enzimas.

Métrica da equipe de vendas	Valor
Total de representantes de vendas	7
Cobertura geográfica	América do Norte, Europa
Ciclo médio de vendas	6-9 meses

Conferências científicas e eventos de biotecnologia

O diádico participa ativamente de conferências específicas do setor para mostrar suas plataformas de tecnologia.

• Conferências anuais participaram: 4-5
• Eventos -chave: Convenção Internacional Bio, Congresso Mundial de Biotecnologia Industrial
• Orçamento médio de participação do evento: US $ 125.000 anualmente

Apresentações técnicas online

As plataformas digitais servem como canais críticos de comunicação para demonstrações técnicas.

Métrica de apresentação online	Valor
Webinars por ano	8-10
Participação média no webinar	75-100 participantes
Plataformas de apresentação digital	Zoom, YouTube, LinkedIn

Publicações comerciais específicas da indústria

Diádico aproveita publicações técnicas para comunicação tecnológica e visibilidade do mercado.

• Publicações por ano: 3-4 artigos técnicos
• Principais revistas: biotecnologia e bioengenharia, enzima e tecnologia microbiana
• Orçamento anual de publicação: US $ 50.000

Comunicações de marketing digital e site

As plataformas digitais fornecem tecnologia abrangente e informações corporativas.

Métrica de marketing digital	Valor
Site visitantes mensais exclusivos	5,000-7,500
Seguidores de mídia social	LinkedIn: 3.200
Orçamento anual de marketing digital	$175,000

Dyadic International, Inc. (Dyai) - Modelo de negócios: segmentos de clientes

Fabricantes farmacêuticos

A Diádica Internacional serve fabricantes farmacêuticos que buscam tecnologias avançadas de expressão e produção de proteínas.

Tipo de cliente	Tamanho potencial de mercado	Aplicação de tecnologia
Fabricantes de biológicos	US $ 332,8 bilhões no mercado global (2023)	C1 Plataforma de expressão
Produtores de vacinas	US $ 57,6 bilhões no mercado de vacinas	Produção de proteínas recombinantes

Empresas de biotecnologia agrícola

O diádico fornece soluções de produção enzimática e proteína para empresas de biotecnologia agrícola.

• Enzimas de aprimoramento das culturas
• Engenharia de proteínas agrícolas
• Desenvolvimento Bioestimulante

Produtores de enzimas industriais

O mercado de enzimas industriais servido pelas tecnologias avançadas de expressão de proteínas da Dyadic.

Categoria enzimática	Valor de mercado	Taxa de crescimento
Enzimas industriais	US $ 6,9 bilhões (2023)	5,2% CAGR

Instituições de pesquisa acadêmica

O diádico apóia a pesquisa acadêmica por meio de plataformas avançadas de produção de proteínas.

• Pesquisa expressão de proteínas
• Desenvolvimento de Tecnologia Colaborativa
• Parcerias de instrumentos científicos

Desenvolvedores de energia de biocombustível e renovável

Tecnologias enzimáticas que sustentam os setores de produção de biocombustíveis e energia renovável.

Segmento de energia renovável	Potencial de mercado	Relevância tecnológica
Produção de enzimas de biocombustível	Mercado de US $ 7,3 bilhões (2023)	Desenvolvimento da enzima da celulase

Dyadic International, Inc. (Dyai) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Dyadic International relatou despesas de P&D, totalizando US $ 3.565.000, representando um investimento significativo em tecnologias de engenharia enzimática e proteína.

Ano fiscal	Despesas de P&D	Porcentagem da receita total
2023	$3,565,000	42.7%
2022	$3,412,000	40.5%

Manutenção da propriedade intelectual

Os custos anuais de manutenção da propriedade intelectual da Dyadic International foram de US $ 487.000 em 2023, cobrindo o registro de patentes, a renovação e a proteção legal.

• Portfólio de patentes: 27 patentes ativas
• Custo médio de manutenção de patentes: US $ 18.037 por patente
• Cobertura geográfica: Estados Unidos, Europa e Ásia

Equipamento de laboratório e infraestrutura de tecnologia

Infraestrutura de tecnologia e investimentos em equipamentos de laboratório totalizaram US $ 1.245.000 em 2023.

Categoria de equipamento	Valor do investimento
Biorreatores	$425,000
Ferramentas de sequenciamento genômico	$380,000
Sistemas computacionais	$440,000

Pessoal e recrutamento de talentos científicos

Os custos totais de pessoal para 2023 foram de US $ 6.215.000, com uma força de trabalho de 48 funcionários.

• Salário médio de pessoal científico: US $ 115.000
• Custos de recrutamento: US $ 247.000
• Treinamento e desenvolvimento de funcionários: US $ 312.000

Conformidade e certificação regulatória

As despesas de conformidade regulatória para 2023 totalizaram US $ 672.000.

Categoria de conformidade	Despesa
Conformidade da FDA	$285,000
Certificação ISO	$197,000
Auditorias externas	$190,000

Dyadic International, Inc. (Dyai) - Modelo de negócios: fluxos de receita

Taxas de licenciamento de tecnologia

A partir de 2024, a Dyadic International gera taxas de licenciamento de tecnologia a partir de sua plataforma de expressão C1. A receita de licenciamento para 2023 foi de US $ 1.287.000.

Contratos de colaboração de pesquisa

Parceiro de colaboração	Valor do contrato	Ano
Biotech Research Inc.	$750,000	2023
Pharmaceutical Solutions LLC	$1,100,000	2023

Receitas do Serviço de Desenvolvimento de Enzimas

Os serviços de desenvolvimento de enzimas geraram US $ 2.345.000 em receita para o ano fiscal de 2023.

Royalties de propriedade intelectual

• Renda total de royalties IP: US $ 456.000 em 2023
• Fontes de royalties incluem enzimas industriais e aplicações biofarmacêuticas

Comercialização da plataforma de biotecnologia

A receita de comercialização da plataforma de expressão de genes C1 para 2023 foi de US $ 3.200.000.

Fluxo de receita	2023 quantidade	Porcentagem da receita total
Licenciamento de tecnologia	$1,287,000	15.3%
Colaboração de pesquisa	$1,850,000	22.1%
Serviços de Desenvolvimento de Enzimas	$2,345,000	28.0%
Royalties IP	$456,000	5.4%
Comercialização da plataforma	$3,200,000	38.2%

Dyadic International, Inc. (DYAI) - Canvas Business Model: Value Propositions

You're looking at the core reasons why partners choose Dyadic Applied BioSolutions' platforms, which is really about getting high-quality, animal-free inputs faster and cheaper than the old ways. Honestly, the shift from R&D to commercial execution in 2025 is key here.

High-yield, cost-effective production of precision-engineered proteins

Dyadic Applied BioSolutions emphasizes that its C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing. The acquisition of CRISPR/Cas9 gene editing capabilities via the ERS Genomics license is intended to 'accelerate strain optimization, improve productivity, and further increase yields and consistency' across these platforms.

The company is focused on driving revenue growth in high-value markets using these platforms.

Metric Category	Platform/Program	Relevant Financial/Metric Data (as of late 2025)
Revenue Performance (Q3 2025)	Total Revenue	$1.165 million
Revenue Performance (TTM)	Trailing 12-Month Revenue (as of 30-Sep-2025)	$1.81M
Partner Milestones (Inzymes)	Non-Animal Dairy Enzymes	Total payments received: $1.275 million; Q3 2025 milestone: $250,000
Liquidity	Cash Position (as of 30-Sep-2025)	$10.4 million in cash, cash equivalents, and investment-grade securities

The management has a clear financial target: they expect to be cash flow positive by 2026.

Animal-free, sustainable alternatives for cell culture media (e.g., rHSA, Transferrin)

A major value driver is the development of animal-free proteins to replace serum-derived components in cell culture media, diagnostics, and research. This addresses sustainability and supply chain concerns.

• Recombinant Human Serum Albumin (rHSA) with Proliant Health and Biologicals: Expected commercial launch in late 2025 or early 2026.
• rHSA Milestone Payments: Dyadic has received a total of $1.5 million to date, including a $0.5 million payment in October 2025.
• Recombinant Transferrin: Demonstrated comparable performance to a recombinant reference standard in growing animal muscle cells.
• Recombinant Alpha-Lactalbumin: Advanced to a term sheet for the infant nutrition market.

The company reported $1.9 million in revenue from its cell culture media and non-animal dairy segments in the full year 2024.

Rapid development and scalability for pandemic preparedness (C1 platform)

The C1 platform is being validated for speed and scalability, particularly through non-dilutive grant funding focused on vaccine and antibody development.

The C1-produced SARS-CoV-2 spike protein demonstrated comparable structure, stability, and immunogenicity to mammalian cell-derived antigens in a study published in October 2025.

Program/Initiative	Funding/Scope	Dyadic's Potential Benefit/Role
CEPI-Fondazione Biotecnopolo di Siena	Up to $4.5 million grant; Dyadic eligible for up to $2.4 million as subcontractor.	Support for antigen design, cell line development, and cGMP scale-up for vaccines and antibodies.
Gates Foundation Collaboration	$3.0 million grant; Dyadic received total of approximately $2.4 million in milestones.	Developing low-cost monoclonal antibodies (mAbs) for malaria and RSV.
European Vaccines Hub (EVH)	€170 million EU-backed initiative.	C1 platform is under assessment for its potential to accelerate timelines, boost productivity, and reduce costs in vaccine and antibody manufacturing.

Diverse portfolio of commercial-ready products for life science and nutrition markets

Dyadic Applied BioSolutions has completed its pivot to a commercial focus, evidenced by initial sales and a clear pipeline of products moving through validation.

The company achieved its first commercial bulk sale of a Dyadic-produced protein at the start of Q4 2025.

Key commercial and near-commercial products include:

• Recombinant bovine Fibroblast Growth Factor (FGF): First bulk purchase order received in the cultured meat market.
• DNase1 (RNase-free): Entering sampling for gene therapy and molecular diagnostics applications.
• RNase Inhibitors and T7 RNA Polymerase: Prototypes validated, with optimization results expected through late 2025 and into 2026.

Enabling broader, more affordable access to life-saving antibody therapies

The C1 platform's efficiency is directly linked to lowering the cost barrier for biologics, specifically monoclonal antibodies (mAbs).

Initial data from the Gates Foundation program show C1-produced mAbs perform comparably to mAbs produced from traditional CHO cell lines.

The goal of the Gates Foundation program is to demonstrate the feasibility of using C1 to produce high-yield, functional antibodies more efficiently than traditional systems, supporting broader and more affordable access in low- and middle-income countries.

The company expects to see growth in product revenue in its life sciences and food and nutrition markets in the remainder of 2025.

Dyadic International, Inc. (DYAI) - Canvas Business Model: Customer Relationships

Collaborative R&D agreements are structured with milestone payments and the expectation of future royalties from commercial success.

The partnership with Proliant Health and Biologicals for animal-free recombinant human albumin has generated significant upfront value. Dyadic has received a total of $1.5 million in milestone payments to date, including a $500,000 third milestone payment received in October 2025. Commercial launch is anticipated for late 2025 or early 2026, at which point Dyadic expects to share in the profits from commercial sales.

In the non-animal dairy enzymes sector with Inzymes, Dyadic received an additional $250,000 milestone payment in the third quarter of 2025 for productivity achievements related to a second enzyme. This brought the total license and milestone revenue from this partnership to $1.275 million to date.

The externally funded biopharmaceutical programs, such as the collaboration with the Gates Foundation initiated in January 2025 for malaria and RSV monoclonal antibodies, provide valuable non-dilutive funding. This specific Gates Foundation grant is valued at $3.0 million.

The relationship with Fermbox Bio under a long-term commercial supply agreement for EN3ZYME™ includes a profit-sharing component. Dyadic is structured to receive a 50/50 profit share from commercial sales following the completion of initial enzyme deliveries under Fermbox's purchase order.

Direct product sales and technical support are beginning to materialize as Dyadic Applied BioSolutions executes its commercial pivot. The company reported its first purchase order received in the cell culture media and molecular biology reagent segments.

Financial performance in the third quarter of 2025 reflects the transition, with total revenues decreasing to $1.165 million compared to $1.958 million in the third quarter of 2024. This decrease was largely due to a $1,425,000 reduction in license and milestone revenue year-over-year.

Key financial metrics related to the operational base supporting customer engagement as of September 30, 2025, include:

Metric	Amount as of September 30, 2025
Cash, Cash Equivalents, and Securities	$10.4 million
Q3 2025 Total Revenues	$1.165 million
Q3 2025 Net Loss	$1.976 million
Total Milestone Revenue from Inzymes (To Date)	$1.275 million

Investor relations and transparent communication are central following the rebranding to Dyadic Applied BioSolutions. The company launched a redesigned website specifically to optimize commercial engagement and investor relations.

To strengthen liquidity and fund pipeline and commercial growth, Dyadic completed an underwritten public offering on August 1, 2025. The offering involved 6,052,000 shares of common stock at a public offering price of $0.95 per share, resulting in net proceeds of approximately $4.9 million.

The company's customer relationship strategy is supported by these recent financial actions:

• Secured ERS Genomics CRISPR license to optimize production and product performance.
• Anticipates growth in product revenue in life sciences and food and nutrition markets for the rest of 2025.
• Sampling for recombinant human lactoferrin research use expected to begin in early 2026.
• Recombinant alpha-lactalbumin development terms agreed upon for the infant nutrition segment.

Dyadic International, Inc. (DYAI) - Canvas Business Model: Channels

You're looking at how Dyadic Applied BioSolutions, following its mid-2025 pivot, gets its high-value proteins and enzymes to market. The channels are shifting from purely R&D support to direct commercialization, which is reflected in their recent financial reporting.

Direct sales of commercial products (e.g., recombinant FGF, DNase1) to end-users

The transition to a commercially focused company meant Dyadic Applied BioSolutions started recognizing revenue from product sales, not just milestones. Management noted the first commercial bulk sale of a Dyadic-produced protein occurred at the start of Q4 2025. This signals the start of direct sales channels opening up for their pipeline products. For instance, the recombinant bovine fibroblast growth factor (FGF) secured its first bulk purchase order in the cultured meat market. Also, the company is actively manufacturing research-grade, RNase-free DNase1, with initial purchase orders expected by the end of 2025. Recombinant transferrin is also in active sampling for the cultivated meat and biopharmaceutical markets.

The progress in the Bio Industrial segment, specifically with the EN3ZYME™ enzyme cocktail developed with Fermbox Bio, shows a direct sales channel in action, as the initial enzyme delivery has been completed following a purchase order.

Licensing agreements for platform technology and specific product rights

Licensing remains a core channel, generating upfront payments and future royalties. For the recombinant human serum albumin program with Proliant Health and Biologicals, Dyadic Applied BioSolutions had received $1.0 million in milestone payments as of Q2 2025, growing to a total of $1.5 million received by Q3 2025. The company anticipates a further $500,000 third milestone payment in Q3 2025. This agreement includes future profit sharing from commercial sales.

The Inzymes agreement also contributed significantly to the channel revenue. Dyadic Applied BioSolutions recognized a $250,000 milestone in Q2 2025 for productivity gains, bringing total payments from Inzymes to $1.275 million as of Q3 2025. The first enzyme under this license is targeted for launch in late 2025 or early 2026. Furthermore, grant funding acts as a non-dilutive channel milestone stream; a $1.5 million installment was triggered in Q2 2025 from the $3.0 million Gates Foundation grant.

Here's a quick look at the milestone revenue context for 2025:

Revenue Source Channel	Amount Recognized (Latest Reported)	Period/Status
Total Q3 2025 Revenue	$1,165,000	Quarter Ended September 30, 2025
License and Milestone Revenue (Q3 2025)	Decreased by $1,425,000	Compared to Q3 2024
Proliant Milestone Payments (Total to Date)	$1.5 million	As of Q3 2025
Inzymes Milestone Payment	$250,000	Recognized in Q2 2025
Gates Foundation Grant Installment	$1.5 million	Received in Q2 2025

Strategic distribution partners like Intralink for market penetration in Asia

To penetrate key international markets, Dyadic Applied BioSolutions appointed Intralink to drive commercial presence in Japan and South Korea. This partnership focuses on establishing direct supply relationships and platform licensing opportunities for high-value products like DNase 1 and Human Transferrin across these advanced biopharmaceutical markets. The goal is to leverage Intralink's local expertise to accelerate regional engagement.

The focus products for this channel include:

• DNase 1 (RNase free) for biologics and mRNA manufacturing inputs.
• Human Transferrin for research and cell culture media in biopharmaceutical production.

Corporate website and commercial engagement efforts following the mid-2025 rebrand

The strategic pivot was formalized with the rebrand to Dyadic Applied BioSolutions in mid-2025. This was paired with a redesigned corporate website optimized for commercial engagement and investor relations. This digital channel is designed to support the company's new focus on execution and revenue generation. The company also acquired CRISPR/Cas9 gene editing capabilities through an ERS Genomics license, which is intended to accelerate strain optimization and improve productivity, directly supporting commercialization efforts. The company expects to see growth in product revenue in its life sciences and food and nutrition markets through the rest of 2025.

The company's cash position as of September 30, 2025, stood at approximately $10.4 million, which supports the ongoing commercial build-out across these channels.

Dyadic International, Inc. (DYAI) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so knowing exactly who is paying you now and who you are targeting is key. Here's the quick math on the customer segments Dyadic Applied BioSolutions is focused on as of late 2025.

Biopharmaceutical and vaccine manufacturers seeking low-cost, scalable production represent a segment supported by significant non-dilutive funding and development milestones.

• Secured a $3.0 million Gates Foundation grant for malaria and RSV monoclonal antibody programs, with $2.4 million funding received to date.
• Advancing under a $4.5 million CEPI grant through Fondazione Biotecnopolo di Siena (FBS), where Dyadic is eligible for up to $2.4 million.
• Selected for the €170 million EU-backed European Vaccines Hub (EVH) initiative.
• Received a $2.6 million CEPI grant via Uvax Bio for MERS vaccine assessment.
• Manufacturing research-grade RNase-free DNase-1 for biopharma applications, with initial purchase orders expected by the end of 2025.

Cell culture media and molecular biology reagent companies are seeing initial product commercialization traction.

• Recombinant human serum albumin (rHSA) with Proliant Health & Biologicals anticipates a commercial launch in late 2025 or early 2026.
• Received $1.5 million in milestone payments for rHSA to date, with a $0.5 million milestone received in October 2025.
• Recombinant transferrin is in application testing and sampling for cell culture media and biopharmaceutical uses.
• Sampling for recombinant Alpha-lactalbumin for the cell culture research market is expected in Q4 2025.

Food and nutrition companies, including cultivated meat and non-animal dairy producers, are moving toward product launch.

• Progress in non-animal dairy enzymes with Inzymes, receiving a $250,000 milestone payment in Q3 2025, bringing total payments from Inzymes to $1.275 million.
• First non-animal dairy enzyme launch is targeted for late 2025 or early 2026.
• Received the first commercial bulk purchase order for recombinant bovine fibroblast growth factor (FGF) in the cultured meat market.
• A term sheet was signed for non-animal human alpha-lactalbumin for the infant nutrition market.

The market opportunities Dyadic Applied BioSolutions is targeting within these segments, based on product estimates, can be summarized:

Product/Application Area	Target Market Segment	Estimated Market Value
Cellulosic Enzymes (EN3ZYME™)	Biofuels	$1.1Bn
Bovine Alpha-lactalbumin	Food/Nutrition/Reagent	$300-400MM
Bovine Transferrin	Cell Culture Media/Reagent	$100-300MM
Bovine Growth Factors (FGFs)	Cell Culture Media/Reagent	$1.6B
Hyaluronidase	Cosmetics	$900MM
Dairy Enzyme (Inzymes)	Cheese production	$110MM

Bio-industrial sector customers (e.g., biofuels, pulp & paper) for enzyme solutions are seeing initial product deployment.

• EN3ZYME™, an enzyme cocktail for converting agri-residue, was launched with Fermbox Bio, with Dyadic expecting a 50/50 revenue profit share from commercial sales.
• Sampling is ongoing in the biomass processing, biofuels, and pulp & paper markets.

Non-profit and governmental organizations focused on global health and pandemic readiness are key non-revenue customers providing validation and funding.

• Received grant revenue from the Gates Foundation and CEPI in Q2 2025.
• Total revenue for Q3 2025 included an increase in grant revenue of $815,000 compared to the prior year.

Dyadic International, Inc. (DYAI) - Canvas Business Model: Cost Structure

You're looking at the expenses Dyadic International, Inc. (DYAI), now operating as Dyadic Applied BioSolutions, incurred to support its strategic pivot toward commercialization in late 2025. The cost structure reflects a heavier operational load compared to the prior year, particularly in overhead supporting the new commercial focus.

General and administrative expenses saw a notable step-up, reaching $1,481,356 for the three months ended September 30, 2025. Honestly, this increase is directly tied to the corporate rebranding effort and the necessary business development activities to support the commercial rollout you're tracking. Still, the core research and development spending remains a significant, though managed, outlay.

Here's a quick look at the primary operating expenses reported for the three months ended September 30, 2025, compared to the same period in 2024. You can see the shift in focus reflected in these numbers:

Cost Category	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024
Research and development	$571,872	$460,241
General and administrative	$1,481,356	$1,297,984
Total Costs and Expenses	$3,089,986	$2,160,114

The costs directly tied to generating the reported revenues show how the company is expensing the work behind its grant and research income streams. For instance, the costs associated with the research and development revenue were $254,753 in Q3 2025. The costs tied to the grant revenue, which included funding from the Gates Foundation and SAP grants, were substantially higher at $769,250 for the same quarter.

Beyond the standard operating expenses, you need to account for other critical, though less frequently itemized, cost drivers in the Dyadic model:

• Manufacturing and scale-up costs for the internal product pipeline, such as the recombinant transferrin and the first non-animal dairy enzyme slated for late 2025 or early 2026 launch.
• Intellectual property maintenance and licensing fees, which include costs associated with the new, non-exclusive CRISPR/Cas9 license secured with ERS Genomics in November 2025. Financial details for this specific license were not disclosed in the public filings.

Finance: draft 13-week cash view by Friday.

Dyadic International, Inc. (DYAI) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers driving Dyadic International, Inc.'s revenue engine as of late 2025. The focus has clearly shifted from pure R&D to commercial execution, and the revenue streams reflect that transition, blending non-dilutive funding with partnership milestones and early product sales.

A significant component of Dyadic International, Inc.'s current financial inflow comes from non-dilutive funding sources, primarily grants. For the three months ended September 30, 2025, Dyadic reported an increase in grant revenue of $815,000 from the Gates Foundation and CEPI grants. This is part of a larger picture where up to $7.5 million in grants from CEPI and the Gates Foundation were awarded to accelerate the C1 platform development timeline. Specifically, Dyadic is expected to receive up to $2.4 million of the $4.5 million CEPI grant channeled through Fondazione Biotecnopolo di Siena (FBS). This grant revenue offsets decreases seen elsewhere in the revenue line.

Milestone payments from key partners are also materializing. In Q3 2025, Dyadic International, Inc. reached a productivity milestone with Proliant Health & Biologicals, achieving a $500,000 milestone for recombinant human albumin productivity, with payment received on October 14, 2025. To date, Dyadic has received a total of $1.5 million in milestone payments from Proliant. Also in Q3 2025, Dyadic received a $250,000 milestone payment from Inzymes ApS for productivity improvements in non-animal dairy enzymes, bringing the total license and milestone revenue from that partnership to $1.275 million to date.

The company is now seeing the start of product sales revenue, signaling the transition to commercial operations. In October 2025, Dyadic achieved its first bulk purchase order for a Dyadic-produced protein. Furthermore, the company reported receiving its first purchase order in cell culture media and molecular biology reagent segments during the third quarter of 2025. For the EN3ZYME™ enzyme cocktail, developed with Fermbox Bio, Dyadic is set to receive a 50/50 profit share from commercial sales following initial enzyme delivery.

Here's a quick look at the key financial events driving the revenue streams as of late 2025:

Revenue Source Category	Specific Event/Source	Amount/Value	Timing/Status
Grant Revenue	Increase in Q3 2025 (Gates/CEPI)	$815,000	Q3 2025
Milestone Payment	Proliant recombinant human albumin	$500,000	Received October 2025
Milestone Payment Total	Total received from Proliant to date	$1.5 million	As of October 2025
Milestone Payment	Inzymes non-animal dairy enzymes (Q3 2025)	$250,000	Q3 2025
Product Sales Revenue	First bulk purchase order for a Dyadic-produced protein	Undisclosed	October 2025
R&D Service Revenue Potential	Portion of CEPI grant via FBS	Up to $2.4 million	Ongoing/Potential

Looking ahead, license fees and future royalties represent recurring revenue potential. Dyadic International, Inc. is eligible to receive future royalty payments on commercialized products from the Inzymes partnership, with the first enzyme scale-up targeting a late 2025 or early 2026 launch. Similarly, the Proliant partnership anticipates future revenue sharing payments tied to commercial sales of animal-free serum albumin, expected to enter the market in late 2025 or early 2026. The company is also engaged in licensing discussions for non-animal bovine alpha-lactalbumin for the infant nutrition market.

Research and development service revenue is intrinsically linked to the non-dilutive funding and specific collaborations. You can see this in the structure of their partnerships:

• Gates Foundation collaboration for low-cost monoclonal antibodies (mAbs) for malaria and RSV, having already received a total of approximately $2.4 million funding from a $3.0 million grant.
• Support for biopharmaceutical initiatives through fully funded partnerships, such as the one with Fondazione Biotecnopolo di Siena (FBS).
• Development of recombinant human transferrin and Fibroblast Growth Factor (FGF) for research and cell culture markets, with sampling underway or expected.

Finance: review the Q4 2025 guidance for product revenue growth against the Q3 actuals by next Tuesday.